

18

I hereby certify that this correspondence is being deposited with the United States Postal Service first class mail in an envelope addressed to:
Assistant Commissioner for Patents, Washington, D.C. 20231, on
December 16, 2002
QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.
By: Tracie Brooks

Atty Docket No: 12E-989110US
Client Ref: G67

TECH CENTER 1600/2900

DEC 30 2002

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Jagdish Parasrampuria; Maxine B. Yonker;
Kenneth E. Schwartz; Marc J. Gurwith
Application No.: 09/526,802

Filed: 3/16/2000

For: **DHEA Composition And Method**

Examiner: Qazi, S.

Art Unit: 1616

AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In response to the Office Action dated September 14, 2002, Applicants respectfully request reconsideration of the above-identified application in view of the following remarks. The following document(s) is/are enclosed herewith:

- 1) A petition to extend the period for response by 3 months.

REMARKS

Status of the Claims.

Claims 1-10 and 36-39 are pending in the application. A listing of these claims is attached as Appendix A.

Substance of the Interview.

Applicants thank Examiners Qazi and Dees for the personal interview conducted with the undersigned attorney and Dr. Young Suh on August 22, 2002. During the interview, Applicants' attorney pointed out that none of the references of record describes or suggests a "pharmaceutical formulation comprising dehydroepiandrosterone (DHEA), at least 85% of which is present as the form I polymorph," as recited in claim 1, much less formulations wherein 90%, 95%, or 99% of the DHEA was present as form I, as recited in various dependent claims. Applicants' attorney explained